NVS
Novartis AG$153.07
LiveJun 12, 2026
Market cap
$292.07B
52w range
112.34 – 170.46
P / E
—
EPS
—
Volume
1.04M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Novartis AG’s valuation06-03today
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)1d
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)1d
- Novartis says rare muscle disease drug shows promise in early trial2d
- Novartis Reports Positive Data for Neuromuscular Disorder Drug2d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $141.00 (-7.89%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.55% | +3.75% | +2.22% | -0.24% | +15.46% | +11.02% | +28.15% | +62.88% | +72.84% | +136.58% | +873.11% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$152.01
Bid
$150.00
1 sh
Ask
$155.00
100 sh
Spread
$5.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
DB · price_targets + analyst_gradesConsensus target
$141.00
-7.89% upside
Low
$112.00
Median
$141.00
High
$170.00
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)globenewswire.com·Jun 12, 2026
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)globenewswire.com·Jun 12, 2026
- Novartis says rare muscle disease drug shows promise in early trialreuters.com·Jun 11, 2026
- Novartis Reports Positive Data for Neuromuscular Disorder Drugzacks.com·Jun 11, 2026
- Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Studybenzinga.com·Jun 11, 2026
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointglobenewswire.com·Jun 11, 2026
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointglobenewswire.com·Jun 11, 2026
- Orionis Biosciences Announces Strategic Collaboration with Novartis to Discover and Develop Molecular Glue Medicinesbusinesswire.com·Jun 10, 2026
Peers
No peer list available for NVS.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|